Back to BARCLAYS PLC BARCLAYS PLC

ABUSABUS
29 quarters

Position history for BARCLAYS PLCBARCLAYS PLC's holdings in ARBUTUS BIOPHARMA CORP

BARCLAYS PLC holds 4.2M shares of ABUS (ARBUTUS BIOPHARMA CORP), worth $20.2M as of 2026-Q2. The position was decreased (-2.5% shares). ABUS represents 0.0% of BARCLAYS PLC's portfolio.

Current Value

$20.2M

Current Shares

4.2M

Total Value Change

+$20.1M

Total Shares Change

+4.2M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
4.2M
-2.5%
$20.2M0.0%$4.80
0
2026-Q1
Increased
4.3M
+1110.1%
$19.4M0.0%$4.69
46
2025-Q4
Increased
356,684
+25.4%
$1.7M0.0%$4.62
32
2025-Q3
Decreased
284,330
-30.1%
$1.3M0.0%$4.46
0
2025-Q2
Increased
406,558
+79.8%
$1.3M0.0%$3.13
39
2025-Q1
Decreased
226,165
-24.2%
$789,3150.0%$3.50
0
2024-Q4
Increased
298,253
+9.6%
$975,2870.0%$3.20
27
2024-Q3
Increased
272,029
+466.3%
$1M0.0%$3.83
40
2024-Q2
Decreased
48,034
-46.1%
$148,4260.0%$3.09
0
2024-Q1
Decreased
89,186
-58.7%
$230,1010.0%$2.58
0
2023-Q4
Increased
215,943
+63.8%
$539,8590.0%$2.50
35
2023-Q3
Increased
131,845
+175.3%
$267,6460.0%$2.03
38
2023-Q2
Decreased
47,895
-16.8%
$110,1590.0%$2.24
0
2023-Q1
Increased
57,558
+88.7%
$174,4010.0%$3.02
35
2022-Q4
Increased
30,504
+566.2%
$71,0740.0%$2.33
23
2022-Q3
Decreased
4,579
-15.5%
$9,0000.0%$1.98
0
2022-Q2
Decreased
5,420
-98.4%
$15,0000.0%$2.70
0
2022-Q1
Decreased
334,796
-38.3%
$997,0000.0%$2.98
0
2021-Q4
Decreased
542,908
-14.6%
$2.1M0.0%$3.88
0
2021-Q3
Increased
635,456
+6310.3%
$2.7M0.0%$4.27
42
2021-Q2
Decreased
9,913
-90.4%
$30,0000.0%$3.15
0
2021-Q1
Increased
102,869
+262x
$342,0000.0%$3.15
38
2020-Q4
New
391
-
$1,0000.0%$3.72
17
2020-Q1
Exited
0
-100.0%
$00.0%$1.12
0
2019-Q4
Decreased
360
-66.8%
$1,0000.0%$2.73
0
2019-Q3
Decreased
1,083
-98.5%
$2,0000.0%$1.52
0
2019-Q2
Increased
74,248
+390.3%
$155,0000.0%$2.08
36
2019-Q1
Increased
15,145
+20.5%
$54,0000.0%$3.58
17
2018-Q4
New
12,565
-
$48,0000.0%$3.88
31

Other major holders of ABUS: MORGAN STANLEY

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used